scispace - formally typeset
G

Gray Ellrodt

Researcher at Berkshire Medical Center

Publications -  30
Citations -  3207

Gray Ellrodt is an academic researcher from Berkshire Medical Center. The author has contributed to research in topics: Disease management (health) & Percutaneous coronary intervention. The author has an hindex of 18, co-authored 30 publications receiving 3041 citations. Previous affiliations of Gray Ellrodt include Cedars-Sinai Medical Center & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Verapamil: A Review of its Pharmacological Properties and Therapeutic Use

TL;DR: Experimental and clinical data suggest that verapamil will become an important and safe addition to existing drug regimens, especially as an agent of choice for the short-term treatment of most cases of paroxysmal supraventricular tachycardias and in the maintenance of sinus rhythm following cardioversion of atrial fibrillation.
Journal ArticleDOI

Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack

TL;DR: Get With the Guidelines–Stroke participation was associated with increased adherence to all stroke performance measures and Markedly improved stroke care was seen in all hospitals regardless of size, geography, and teaching status.
Journal ArticleDOI

Evidence-Based Disease Management

TL;DR: This work presents a method for developing and implementing evidence-based clinical guidelines, clinical pathways, and algorithms and describes the creation of systems to measure and report processes and outcomes that could drive quality improvement in diabetes care.
Journal ArticleDOI

Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

TL;DR: Evidence indicates that certain slow-channel antagonists may be useful in other cardiocirculatory disorders, such as acute pulmonary edema, acute hypertensive emergencies and obstructive cardiomyopathies, whose indications, if confirmed, will broaden the clinical usefulness of this class of compounds.